• Explore /
  • Poster
  • / Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921.

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921.

Abstract Poster

Authors

Daniel Petrylak

Daniel Peter Petrylak

Smilow Cancer Hospital at Yale University, New Haven, CT

Daniel Peter Petrylak , Neal D. Shore , Mostefa Bennamoun , Raffaele Ratta , Josep M. Piulats , Ben Li , Charles Schloss , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03834506

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS262)

Abstract #

TPS262

Poster Bd #

P6

Abstract Disclosures

Similar Posters

First Author: Sumit Kumar Subudhi

First Author: Simon J. Crabb

First Author: Neeraj Agarwal

First Author: Srikala S. Sridhar